JP6879670B2 - Topical composition for concealing wrinkles and / or pores - Google Patents
Topical composition for concealing wrinkles and / or pores Download PDFInfo
- Publication number
- JP6879670B2 JP6879670B2 JP2016069071A JP2016069071A JP6879670B2 JP 6879670 B2 JP6879670 B2 JP 6879670B2 JP 2016069071 A JP2016069071 A JP 2016069071A JP 2016069071 A JP2016069071 A JP 2016069071A JP 6879670 B2 JP6879670 B2 JP 6879670B2
- Authority
- JP
- Japan
- Prior art keywords
- powder
- external composition
- wrinkles
- pores
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 117
- 230000037303 wrinkles Effects 0.000 title claims description 59
- 239000011148 porous material Substances 0.000 title claims description 39
- 230000000699 topical effect Effects 0.000 title 1
- 239000000843 powder Substances 0.000 claims description 166
- 229920002472 Starch Polymers 0.000 claims description 49
- 235000019698 starch Nutrition 0.000 claims description 48
- 239000008107 starch Substances 0.000 claims description 48
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 34
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 8
- 239000002628 heparin derivative Substances 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 229940048053 acrylate Drugs 0.000 description 33
- 239000006185 dispersion Substances 0.000 description 29
- 229920001499 Heparinoid Polymers 0.000 description 22
- 239000002554 heparinoid Substances 0.000 description 22
- 230000036548 skin texture Effects 0.000 description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 230000014759 maintenance of location Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000035699 permeability Effects 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- -1 polysiloxane Polymers 0.000 description 13
- 239000002734 clay mineral Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 239000010445 mica Substances 0.000 description 9
- 229910052618 mica group Inorganic materials 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 235000012239 silicon dioxide Nutrition 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 239000005995 Aluminium silicate Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 235000012211 aluminium silicate Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229910021536 Zeolite Inorganic materials 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000010457 zeolite Substances 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229910052903 pyrophyllite Inorganic materials 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 229940047670 sodium acrylate Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- UQOXSYQRUXKNQH-UHFFFAOYSA-N 1-hexadecoxyhexadecane;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC UQOXSYQRUXKNQH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- JWKSQNWLEIABLH-UHFFFAOYSA-N 1-octan-2-yloxydodecane Chemical compound CCCCCCCCCCCCOC(C)CCCCCC JWKSQNWLEIABLH-UHFFFAOYSA-N 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- GQQNRZHWHWHOLI-UHFFFAOYSA-N 11-(2-decyltetradecoxymethyl)tricosane Chemical compound CCCCCCCCCCCCC(CCCCCCCCCC)COCC(CCCCCCCCCC)CCCCCCCCCCCC GQQNRZHWHWHOLI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WAUOHBVKOUNIAX-UHFFFAOYSA-N 2-(dimethylamino)-3-oxopent-4-ene-1-sulfonic acid Chemical class OS(=O)(=O)CC(N(C)C)C(=O)C=C WAUOHBVKOUNIAX-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- IKVCSHRLYCDSFD-UHFFFAOYSA-N 2-hexadecanoyloxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCC IKVCSHRLYCDSFD-UHFFFAOYSA-N 0.000 description 1
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241001400590 Richia Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229910052620 chrysotile Inorganic materials 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- YGANSGVIUGARFR-UHFFFAOYSA-N dipotassium dioxosilane oxo(oxoalumanyloxy)alumane oxygen(2-) Chemical compound [O--].[K+].[K+].O=[Si]=O.O=[Al]O[Al]=O YGANSGVIUGARFR-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical group 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052621 halloysite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052627 muscovite Inorganic materials 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- CWBIFDGMOSWLRQ-UHFFFAOYSA-N trimagnesium;hydroxy(trioxido)silane;hydrate Chemical compound O.[Mg+2].[Mg+2].[Mg+2].O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-] CWBIFDGMOSWLRQ-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Description
本発明は、粉体の分散安定性が向上している、シワ及び/又は毛穴の隠蔽用の外用組成物に関する。 The present invention relates to an external composition for concealing wrinkles and / or pores, which has improved powder dispersion stability.
近年、美肌に対する関心の高まりを受け、自然な若々しい印象を与えるためのエイジングケアに注目が集まっている。とりわけ、シワや開いた毛穴は、肌印象を悪化させる大きな要因になっており、シワや毛穴に対する対処は美容上の大きな関心事になっている。 In recent years, with the growing interest in beautiful skin, attention has been focused on aging care to give a natural and youthful impression. In particular, wrinkles and open pores are major factors that worsen the impression of the skin, and coping with wrinkles and pores has become a major cosmetic concern.
従来、シワや毛穴への対処策として、二酸化ケイ素や酸化チタン等の粉体が含む外用組成物を使用して、シワや毛穴を隠蔽して目立たなくする美容法が知られている。しかしながら、粉体は分散安定性が悪いため、粉体を含む外用組成物は、製剤化の過程でダマが発生したり、経時的に粉体の沈降や凝集が生じたりするという問題点がある。そのため、シワや毛穴の隠蔽に使用される外用組成物は、粉体の分散安定性を向上させる製剤化技術が求められている。 Conventionally, as a countermeasure against wrinkles and pores, a beauty method has been known in which wrinkles and pores are concealed and made inconspicuous by using an external composition containing powders such as silicon dioxide and titanium oxide. However, since the powder has poor dispersion stability, the external composition containing the powder has a problem that lumps are generated in the process of formulation and the powder is settled or agglomerated over time. .. Therefore, for external compositions used for concealing wrinkles and pores, a formulation technique for improving the dispersion stability of powder is required.
これまでに、外用組成物中で粉体の分散安定性を高める製剤化技術について種々提案されている。例えば、特許文献1には、水中油型乳化組成物において、油層に、疎水化処理粉体、50質量%以上のシリコーン油、並びにポリオキシアルキレン変性ポリシロキサン及び/又はイソステアリン酸を含有させることによって、粉体の分散安定性を向上させ得ることが報告されている。また、特許文献2には、水中油型乳化組成物において、油層に、特定量のシリコーン油、HLB5以下の両親媒性物質、特定のアクリルシリコーンを含有させることによって、粉体に良好な分散安定性を備えさせ得ることが報告されている。特許文献3には、アクリロイルジメチルタウリン塩とアクリル酸ヒドロキシエチルとの共重合体を含む水相と、粉体を含む油相を含む水中油型乳化組成物は、粉体の凝集や沈降を改善できることが報告されている。特許文献4には、化粧料において、粉体と特定の両末端シリコーン変性グリセリンとを共存させることにより、粉体の分散安定性が向上することが報告されている。 So far, various formulation techniques for enhancing the dispersion stability of powders in external compositions have been proposed. For example, in Patent Document 1, in an oil-in-water emulsified composition, the oil layer contains a hydrophobized powder, 50% by mass or more of silicone oil, and a polyoxyalkylene-modified polysiloxane and / or isostearic acid. , It has been reported that the dispersion stability of powder can be improved. Further, Patent Document 2 states that in an oil-in-water emulsified composition, a specific amount of silicone oil, an amphipathic substance having an HLB of 5 or less, and a specific acrylic silicone are contained in an oil layer, so that the powder has good dispersion stability. It has been reported that it can be equipped with sex. According to Patent Document 3, an oil-in-water emulsified composition containing an aqueous phase containing a copolymer of acryloyldimethyltaurine salt and hydroxyethyl acrylate and an oil phase containing powder improves powder aggregation and sedimentation. It has been reported that it can be done. Patent Document 4 reports that the dispersion stability of powder is improved by coexistence of powder and specific biterminal silicone-modified glycerin in cosmetics.
しかしながら、特許文献1〜4では、いずれも、非イオン性界面活性剤に該当する化合物を使用することにより、乳化組成物中での粉体の分散安定性を向上させているため、HLBのバランスが崩れた場合等で転相し易く、乳化安定性に影響を与えたり、配合できる成分が制約されたりするという欠点がある。更に、特許文献1〜4の製剤化技術では、粉体を多く配合する場合には、十分な分散安定性を確保できなくなることもある。 However, in Patent Documents 1 to 4, the HLB balance is improved because the dispersion stability of the powder in the emulsified composition is improved by using the compound corresponding to the nonionic surfactant. There is a drawback that the phase is easily changed when the mixture is broken, which affects the emulsion stability and restricts the components that can be blended. Further, in the formulation techniques of Patent Documents 1 to 4, when a large amount of powder is blended, sufficient dispersion stability may not be ensured.
このような従来技術を背景として、シワ及び/又は毛穴の隠蔽に使用される外用組成物において、粉体の分散安定性を向上させる新たな技術の開発が求められている。 Against the background of such conventional techniques, the development of new techniques for improving the dispersion stability of powders in external compositions used for concealing wrinkles and / or pores is required.
本発明の目的は、シワ及び/又は毛穴の隠蔽に使用される外用組成物において、粉体の分散安定性を向上させる製剤化技術を提供することである。 An object of the present invention is to provide a formulation technique for improving the dispersion stability of a powder in an external composition used for concealing wrinkles and / or pores.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、シワ及び/又は毛穴の隠蔽に使用される外用組成物において、粉体と共にヘパリン類似物質を配合すると、粉体の分散安定性が著しく向上し、沈降、凝集、ダマの形成が抑制され、優れた製剤安定性を備え得ることを見出した。 As a result of diligent studies to solve the above problems, the present inventor has found that when a heparin-like substance is blended with a powder in an external composition used for concealing wrinkles and / or pores, the dispersion stability of the powder is obtained. It was found that the amount was significantly improved, sedimentation, aggregation, and formation of lumps were suppressed, and excellent formulation stability could be provided.
また、本発明者は、前記外用組成物に、更にアクリル酸デンプンを配合すると、粉体が毛穴やシワに入りこみ易くなり、更にシワや毛穴に入り込んだ粉体が皮膚に馴染んで本来の肌と似た質感を呈することができ、毛穴やシワに対して優れた隠蔽効果を奏し得ることを見出した。更に、当該外用組成物は、粉体がシワや毛穴に一旦入りこむと離脱し難くなり、隠蔽効果の持続性の点でも優れていることを見出した。 In addition, when the external composition is further blended with starch acrylate, the present inventor makes it easier for the powder to penetrate into the pores and wrinkles, and the powder that has entered the wrinkles and pores becomes familiar with the skin and becomes the original skin. It has been found that it can exhibit a similar texture and can exert an excellent concealing effect on pores and wrinkles. Furthermore, it has been found that the external composition is excellent in terms of sustainability of the hiding effect, because once the powder has entered the wrinkles and pores, it is difficult to remove the powder.
本発明は、これらの知見に基づいて更に検討を重ねることにより、完成したものである。即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. シワ及び/又は毛穴の隠蔽に使用される外用組成物であって、粉体、及びヘパリン類似物質を含有することを特徴とする、外用組成物。
項2. 前記粉体の平均粒子径が0.1〜30μmである、項1に記載の外用組成物。
項3. 更にアクリル酸澱粉を含む、項1又は2に記載の外用組成物。
項4. 前記粉体として、屈折率が1.3〜2.0の粉体及び屈折率が2.2〜2.8の粉体を含む、項1〜3のいずれかに記載の外用組成物。
項5. 前記粉体として、酸化鉄を含む、項1〜4のいずれかに記載の外用組成物。
The present invention has been completed by further studies based on these findings. That is, the present invention provides the inventions of the following aspects.
Item 1. An external composition used for concealing wrinkles and / or pores, which comprises a powder and a heparinoid.
Item 2. Item 2. The external composition according to Item 1, wherein the powder has an average particle size of 0.1 to 30 μm.
Item 3. Item 2. The external composition according to Item 1 or 2, further comprising acrylic acid starch.
Item 4. Item 2. The external composition according to any one of Items 1 to 3, wherein the powder contains a powder having a refractive index of 1.3 to 2.0 and a powder having a refractive index of 2.2 to 2.8.
Item 5. Item 2. The external composition according to any one of Items 1 to 4, which contains iron oxide as the powder.
本発明の外用組成物は、粉体の分散安定性が向上しているので、液状に製剤化した場合には粉体の沈降や凝集を抑制でき、また半固形状(クリーム状等)に製剤化した場合には、粉体が凝集したり、ダマになったりするのを抑制できるので、優れた製剤安定性を有している。 Since the external composition of the present invention has improved dispersion stability of powder, it can suppress sedimentation and aggregation of powder when it is formulated in liquid form, and it is formulated in a semi-solid form (cream-like, etc.). When it is formed, it can prevent the powder from agglomerating or becoming lumpy, so that it has excellent formulation stability.
更に、本発明の外用組成物の一態様では、粉体がシワや毛穴に入りこみ易くなり、更にシワや毛穴に入り込んだ粉体が皮膚に馴染んで本来肌と同じ質感を呈することができるので、シワや毛穴部分を本来の肌質と同じ質感に仕上げ、シワや毛穴を目立ち難くすることができる。また、本発明の外用組成物の一態様では、シワや毛穴に一旦入り込んだ粉体が離脱し難いため、日常生活における身体動作を行っても粉体がシワ部や毛穴部に保持され、シワや毛穴の隠蔽効果を持続させることができる。 Further, in one aspect of the external composition of the present invention, the powder easily penetrates into wrinkles and pores, and the powder that has penetrated into wrinkles and pores can be blended into the skin to give the same texture as the skin. Wrinkles and pores can be finished with the same texture as the original skin, making wrinkles and pores less noticeable. Further, in one aspect of the external composition of the present invention, since the powder once entered into the wrinkles and pores is difficult to be separated, the powder is retained in the wrinkles and pores even when the body moves in daily life, and the wrinkles are formed. And the effect of hiding pores can be sustained.
本発明の外用組成物は、シワ及び/又は毛穴の隠蔽に使用される外用組成物であって、粉体、及びヘパリン類似物質を含有することを特徴とする。以下、本発明の外用組成物について詳述する。 The external composition of the present invention is an external composition used for concealing wrinkles and / or pores, and is characterized by containing powder and a heparin-like substance. Hereinafter, the external composition of the present invention will be described in detail.
なお、本明細書において、「粉体侵入性」とは、シワや毛穴に対する粉体の入り込み易さを指し、「肌質感」とは、粉体が入りこんだシワや毛穴部分において、本来の肌部分と違和感なく視覚的に似た肌質を呈する外観状態を指し、「粉体保持性」とは、シワや毛穴に一旦入り込んだ粉体が離脱し難く、シワや毛穴において保持される特性を指す。 In the present specification, "powder permeability" refers to the ease with which powder can enter into wrinkles and pores, and "skin texture" refers to the original skin in the wrinkles and pores where powder has entered. It refers to the appearance state that visually resembles the skin quality to the part, and "powder retention" refers to the characteristic that powder once entered into wrinkles and pores is difficult to separate and is retained in wrinkles and pores. Point to.
粉体
本発明は、シワや毛穴を隠蔽するために、粉体を含有する。本発明で使用される粉体は、従来、外用組成物においてシワや毛穴の隠蔽目的で用いられている隠蔽性無機粉体であればよい。このような粉体として、具体的には、水や有機溶剤に対して溶解及び膨潤しない特性を有するもの、即ち、不溶性非膨潤性の粉体が挙げられる。
Powder The present invention contains powder to conceal wrinkles and pores. The powder used in the present invention may be any concealing inorganic powder conventionally used for the purpose of concealing wrinkles and pores in the external composition. Specific examples of such powders include those having a property of not dissolving and swelling in water or an organic solvent, that is, insoluble non-swelling powders.
不溶性非膨潤性の粉体の種類については、特に制限されないが、例えば、カオリン系粘土鉱物、パイロフィライト系粘土鉱物、雲母系粘土鉱物、緑泥石系粘土鉱物、焼成粘土鉱物、ゼオライト系粘土鉱物、金属酸化物等が挙げられる。 The type of insoluble non-swellable powder is not particularly limited, but for example, kaolin-based clay mineral, pyrophyllite-based clay mineral, mica-based clay mineral, green mudstone-based clay mineral, calcined clay mineral, and zeolite-based clay mineral. , Metal oxides and the like.
カオリン系粘土鉱物としては、具体的には、カオリン(カオリナイト)、ハロイサイト、ナクライト、デッカイト、クリソタイル等が挙げられる。 Specific examples of kaolin-based clay minerals include kaolin (kaolinite), halloysite, nacrite, deckite, and chrysotile.
パイロフィライト系粘土鉱物としては、具体的には、タルク、パイロフィライト等が挙げられる。 Specific examples of the pyrophyllite-based clay mineral include talc and pyrophyllite.
雲母系粘土鉱物としては、具体的には、四角雲母(マイカ)、絹雲母(セリサイト)、白雲母(マスコバイト)、金雲母(フロゴバイト)、合成雲母、紅雲母(リチア雲母)、黒雲母(バイオタイト)等が挙げられる。 Specific examples of mica-based clay minerals include square mica (mica), sericite (serisite), muscovite (mascovite), gold mica (frogobite), synthetic mica, red mica (richia mica), and black mica. (Biotight) and the like.
緑泥石系粘土鉱物としては、具体的には、クロライト等を好ましく用いることができる。 Specifically, chlorite or the like can be preferably used as the chlorite-based clay mineral.
焼成粘土鉱物としては、具体的には、焼成雲母、焼成タルク、焼成セリサイト等が挙げられる。 Specific examples of the calcined clay mineral include calcined mica, calcined talc, and calcined sericite.
ゼオライト系粘土鉱物としては、具体的には、天然ゼオライト、合成ゼオライト等が挙げられる。 Specific examples of the zeolite-based clay mineral include natural zeolite and synthetic zeolite.
金属酸化物としては、具体的には、酸化鉄(赤酸化鉄(三二酸化鉄、ベンガラ)、黄酸化鉄、黄色三二酸化鉄、黒酸化鉄)、酸化亜鉛(亜鉛華)、酸化ジルコニウム、酸化チタン、酸化アルミニウム、酸化マグネシウム、シリカ、二酸化ケイ素、二酸化ケイ素・アルミナ複合化粉体、二酸化ケイ素・マグネシウム複合化粉体等が挙げられる。 Specific examples of the metal oxide include iron oxide (red iron oxide (iron sesquioxide, red iron oxide), yellow iron oxide, yellow sesquioxide, black iron oxide), zinc oxide (zinc flower), zirconium oxide, and oxidation. Examples thereof include titanium, aluminum oxide, magnesium oxide, silica, silicon dioxide, silicon dioxide / alumina composite powder, and silicon dioxide / magnesium composite powder.
これらの粉体の中でも、分散安定性をより一層向上させるという観点から、或は、後述するアクリル酸デンプンを配合した際に達成される粉体侵入性、肌質感、及び粉体保持性の向上をより一層顕著ならしめるという観点から、好ましくは酸化チタン、二酸化ケイ素、タルク、カオリン、酸化鉄が挙げられる。 Among these powders, improvement of powder permeability, skin texture, and powder retention achieved from the viewpoint of further improving dispersion stability or when starch acrylate, which will be described later, is blended. From the viewpoint of making the powder even more prominent, titanium oxide, silicon dioxide, talc, kaolin, and iron oxide are preferable.
また、これらの粉体は、必要に応じて、表面処理が施され、表面特性が改質されていてもよい。 Further, these powders may be subjected to surface treatment to modify the surface characteristics, if necessary.
本発明に使用される粉体の平均粒子径については、シワや毛穴に対する隠蔽効果を奏し得ることを限度として特に制限されないが、例えば、0.1〜30μmが挙げられる。粉体の侵入性をより一層向上させるという観点から、粉体の平均粒子径として、好ましくは0.1〜20μm、更に好ましくは0.1〜15μm、特に好ましくは0.1〜10μm、最も好ましくは0.1〜5μmが挙げられる。従来技術では、このような平均粒子径の粉体は、粉体の保持特性が劣る傾向があったが、本発明の外用組成物では、このような平均粒子径の粉体であっても、後述するアクリル酸デンプンを配合することによって優れた粉体の保持特性を備えさせることが可能になる。なお、粉体の平均粒子径はレーザー回析・散乱法にて測定される値(D50)である。 The average particle size of the powder used in the present invention is not particularly limited as long as it can exert a concealing effect on wrinkles and pores, and examples thereof include 0.1 to 30 μm. From the viewpoint of further improving the permeability of the powder, the average particle size of the powder is preferably 0.1 to 20 μm, more preferably 0.1 to 15 μm, particularly preferably 0.1 to 10 μm, and most preferably 0.1 to 10 μm. Is 0.1 to 5 μm. In the prior art, such powders having an average particle size tended to have inferior powder retention characteristics, but in the external composition of the present invention, even powders having such an average particle size can be used. By blending starch acrylate, which will be described later, it becomes possible to provide excellent powder retention characteristics. The average particle size of the powder is a value (D50) measured by a laser diffraction / scattering method.
本発明の外用組成物において、粉体は、1種単独で又は2種以上組み合わせて使用してもよく、使用する粉体の種類は、付与すべき肌質感の程度等に応じて適宜選定すればよい。 In the external composition of the present invention, the powder may be used alone or in combination of two or more, and the type of powder used should be appropriately selected according to the degree of skin texture to be imparted and the like. Just do it.
例えば、酸化鉄は、ヘパリン類似物質と共存させることにより、色調が明るくなり、発色性が向上するので、本発明の外用組成物にヘパリン類似物質が含まれる場合には、酸化鉄は、肌質感を更に高め、シワをより一層目立たなくする上で特に好適である。 For example, when iron oxide coexists with a heparinoid, the color tone becomes brighter and the color development property is improved. Therefore, when the external composition of the present invention contains a heparinoid, the iron oxide has a skin texture. It is particularly suitable for further increasing the amount of wrinkles and making wrinkles more inconspicuous.
例えば、屈折率が2.0以下、好ましくは1.3〜2.0程度の粉体(以下、低屈折率粉体と表記することもある)は、シワや毛穴に入り込んで透明感を呈し、自然な印象を与えることができるので、透明感に優れた肌質感を付与することを重視する場合には、好適に使用される。屈折率が1.3〜2.0程度の粉体としては、具体的には、二酸化ケイ素、タルク、カオリン等が挙げられる。 For example, a powder having a refractive index of 2.0 or less, preferably about 1.3 to 2.0 (hereinafter, may be referred to as a low refractive index powder) penetrates into wrinkles and pores and exhibits a transparent feeling. Since it can give a natural impression, it is preferably used when it is important to give a skin texture excellent in transparency. Specific examples of the powder having a refractive index of about 1.3 to 2.0 include silicon dioxide, talc, and kaolin.
例えば、屈折率が2.0超、好ましくは2.2〜2.8程度の粉体(以下、高屈折率粉体と表記することもある)は、シワや毛穴の周辺の皮膚色に馴染み易く、粉体が入り込んだシワや毛穴部分の違和感を低減させることができので、周辺の皮膚色との違和感の低減を重視する場合には、好適に使用される。屈折率が2.2〜2.8程度の粉体としては、具体的には、酸化チタン等が挙げられる。 For example, a powder having a refractive index of more than 2.0, preferably about 2.2 to 2.8 (hereinafter, may be referred to as a high refractive index powder) is familiar with the skin color around wrinkles and pores. It is easy to use and can reduce the discomfort of wrinkles and pores in which powder has entered. Therefore, it is preferably used when it is important to reduce the discomfort with the surrounding skin color. Specific examples of the powder having a refractive index of about 2.2 to 2.8 include titanium oxide.
また、本発明で使用される粉体の好適な一態様として、低屈折率粉体と高屈折率粉体の組み合わせが挙げられる。低屈折率粉体と高屈折率粉体を併用することによって、透明感に優れ、しかも周辺の皮膚色との違和感が低減された肌質感を実現することが可能になる。低屈折率粉体と高屈折率粉体を組み合わせて使用する場合、これらの比率については、特に制限されないが、例えば、低屈折率粉体100重量部当たり、高屈折率粉体が5〜300重量部、好ましくは10〜200重量部、更に好ましくは10〜150重量部が挙げられる。 Further, as a preferable aspect of the powder used in the present invention, a combination of a low refractive index powder and a high refractive index powder can be mentioned. By using the low-refractive index powder and the high-refractive index powder in combination, it is possible to realize a skin texture having excellent transparency and less discomfort with the surrounding skin color. When the low refractive index powder and the high refractive index powder are used in combination, the ratio thereof is not particularly limited, but for example, 5 to 300 parts of the high refractive index powder per 100 parts by weight of the low refractive index powder. By weight, preferably 10 to 200 parts by weight, more preferably 10 to 150 parts by weight.
本発明の外用組成物における粉体の含有量については、特に制限されないが、例えば、1〜25重量%程度、好ましくは1〜20重量%程度、更に好ましくは1〜15重量%程度、特に好ましくは1〜10重量%程度が挙げられる。 The content of the powder in the external composition of the present invention is not particularly limited, but is, for example, about 1 to 25% by weight, preferably about 1 to 20% by weight, more preferably about 1 to 15% by weight, and particularly preferably about 1 to 15% by weight. Is about 1 to 10% by weight.
ヘパリン類似物質
本発明の外用組成物は、ヘパリン類似物質を含有する。本発明の外用組成物では、ヘパリン類似物質によって、粉体の分散安定性の向上が図られ、沈降、凝集、ダマの形成等を抑制することが可能になる。また、粉体の分散安定性を向上させることにより、皮膚に塗布した際にシワや毛穴において粉体侵入性を均一にすることも可能になる。
Heparinoid The external composition of the present invention contains a heparinoid. In the external composition of the present invention, the heparin-like substance improves the dispersion stability of the powder and makes it possible to suppress sedimentation, aggregation, formation of lumps, and the like. Further, by improving the dispersion stability of the powder, it is possible to make the powder permeability uniform in wrinkles and pores when applied to the skin.
ヘパリン類似物質とは、コンドロイチン多硫酸等の多硫酸化ムコ多糖であり、保湿作用、抗炎症作用、血行促進作用等を有することが知られている公知の薬剤である。 The heparinoid is a polysulfated mucopolysaccharide such as chondroitin polysulfate, and is a known drug known to have a moisturizing effect, an anti-inflammatory effect, a blood circulation promoting effect, and the like.
本発明で使用されるヘパリン類似物質の由来については、特に制限されないが、例えば、ムコ多糖類を多硫酸化することにより得られたもの、食用獣の組織(例えば、ウシやブタ等の気管軟骨を含む肺臓)から抽出したもの等が挙げられる。本発明の外用組成物では、ヘパリン類似物質として、日本薬局方外医薬品規格に収戴されているヘパリン類似物質が好適に使用される。 The origin of the heparinoid used in the present invention is not particularly limited, but for example, those obtained by polysulfating mucopolysaccharides, tissues of edible animals (for example, tracheal cartilage of cattle, pigs, etc.) Examples include those extracted from (lungs containing). In the external composition of the present invention, as the heparinoid, the heparinoid contained in the Japanese Pharmacopoeia non-pharmaceutical standard is preferably used.
本発明の外用組成物において、ヘパリン類似物質の含有量については、特に制限されないが、例えば、0.1重量%以上、好ましくは0.1〜1重量%、更に好ましくは0.1〜0.5重量%が挙げられる。 The content of the heparinoid in the external composition of the present invention is not particularly limited, but is, for example, 0.1% by weight or more, preferably 0.1 to 1% by weight, more preferably 0.1 to 0%. 5% by weight is mentioned.
また、本発明の外用組成物において、粉体に対するヘパリン類似物質の比率については、特に制限されないが、例えば、粉体100重量部当たり、ヘパリン類似物質が、0.1重量部以上、好ましくは0.1〜500重量部、更に好ましくは0.2〜300重量部、特に好ましくは0.2〜200重量部が挙げられる。 Further, in the external composition of the present invention, the ratio of the heparinoid to the powder is not particularly limited, but for example, the amount of the heparinoid is 0.1 part by weight or more, preferably 0 per 100 parts by weight of the powder. .1 to 500 parts by weight, more preferably 0.2 to 300 parts by weight, and particularly preferably 0.2 to 200 parts by weight.
アクリル酸デンプン
本発明の外用組成物は、必要に応じて、アクリル酸デンプンを含むことができる。本発明の外用組成物では、粉体及びヘパリン類似物質と共にとアクリル酸デンプンを含むことによって、粉体侵入性、肌質感、及び粉体保持性を向上させることができ、優れた隠蔽効果を持続的に奏させることが可能になる。限定的な解釈を望むものではないが、本発明の外用組成物においてアクリル酸デンプンを含む場合には、皮膚に塗布された粉体がアクリル酸デンプンで覆われていることにより、粉体による表面の凹凸が均一になり、それによって、粉体侵入性が高まると共に、粉体に入射する光や粉体から反射する光をより均一にすることにより肌質感を向上させることが可能になっていると考えられる。また、本発明の外用組成物が塗布されたシワや毛穴部分がアクリル酸デンプンによって覆われ、粉体保持性が向上すると考えられる。
Starch Acrylic Acid The external composition of the present invention may contain starch acrylate, if necessary. In the external composition of the present invention, the powder permeability, the texture of the skin, and the powder retention can be improved by containing the powder and the heparinoid and the starch acrylate, and the excellent hiding effect is maintained. It becomes possible to play the target. Although not limited interpretation is desired, when starch acrylate is contained in the external composition of the present invention, the powder applied to the skin is covered with starch acrylate, so that the surface of the powder is formed. The unevenness of the powder becomes uniform, which enhances the penetration of the powder and makes it possible to improve the texture of the skin by making the light incident on the powder and the light reflected from the powder more uniform. it is conceivable that. Further, it is considered that the wrinkles and pores to which the external composition of the present invention is applied are covered with starch acrylate, and the powder retention property is improved.
アクリル酸デンプンとは、デンプンがアクリル酸によって化学修飾されているデンプン誘導体である。本発明に使用されるアクリル酸デンプンの種類については、特に制限されないが、例えば、アクリル酸デンプン300、アクリル酸デンプン1000、デンプン・アクリル酸ナトリウムグラフト重合体等が挙げられる。これらのアクリル酸デンプンの中でも、粉体侵入性、肌質感、及び粉体保持性をより一層向上させるという観点から、好ましくはアクリル酸デンプン300、アクリル酸デンプン1000、更に好ましくはアクリル酸デンプン1000が挙げられる。 Acrylic acid starch is a starch derivative in which starch is chemically modified with acrylic acid. The type of starch acrylate used in the present invention is not particularly limited, and examples thereof include starch acrylate 300, starch acrylate 1000, starch / sodium acrylate graft polymer, and the like. Among these starch acrylates, starch acrylate 300, starch acrylate 1000, and starch acrylate 1000 are more preferable from the viewpoint of further improving powder permeability, skin texture, and powder retention. Can be mentioned.
また、アクリル酸デンプンを構成する原料デンプンの種類については、特に制限されないが、例えば、トウモロコシデンプン、小麦デンプン、馬鈴薯デンプン、タピオカデンプン、米デンプン、甘藷デンプン、サゴデンプン、ソラマメデンプン、緑豆デンプン、大豆デンプン、小豆デンプン等が挙げられる。 The type of raw material starch constituting the acrylate starch is not particularly limited, but for example, corn starch, wheat starch, potato starch, tapioca starch, rice starch, sweet potato starch, sago starch, soramame starch, green bean starch, and soybean starch. , Azuki starch and the like.
これらのアクリル酸デンプンは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These starch acrylates may be used alone or in combination of two or more.
アクリル酸デンプンは、公知の方法により調製したものを使用してもよく、また市販品を使用してもよい。アクリル酸デンプンの市販品としては、例えば、アクリル酸デンプン300としては、商品名「サンウェットIM−300MPS」(三洋化成工業株式会社製);アクリル酸デンプン1000としては、商品名「サンウェットIM−1000」、商品名「サンウェットサンウェットIM−1000MPS」(いずれも三洋化成工業株式会社製);デンプン・アクリル酸ナトリウムグラフト重合体としては、商品名「サンフレッシュST−100MC」(三洋化成工業株式会社製)等が挙げられる。 As the starch acrylate, one prepared by a known method may be used, or a commercially available product may be used. As a commercially available product of starch acrylate, for example, the starch acrylate 300 has a trade name of "Sunwet IM-300MPS" (manufactured by Sanyo Chemical Industries, Ltd.); the starch acrylate 1000 has a trade name of "Sunwet IM-". 1000 ", trade name" Sun Wet Sun Wet IM-1000MPS "(both manufactured by Sanyo Chemical Industries, Ltd.); as a starch-sodium acrylate graft polymer, trade name" Sun Fresh ST-100MC "(SANYO CHEMICAL INDUSTRIES CO., LTD.) (Made by company), etc.
本発明の外用組成物において、アクリル酸デンプンを含有させる場合、その含有量については、特に制限されないが、例えば、0.1〜10重量%が挙げられる。粉体侵入性、肌質感、及び粉体保持性をより一層向上させるという観点から、本発明の外用組成物におけるアクリル酸デンプンの含有量として、好ましくは、0.1〜5重量%、更に好ましくは0.1〜3重量%、特に好ましくは0.1〜2重量%、最も好ましくは0.1〜1重量%が挙げられる。 When starch acrylate is contained in the external composition of the present invention, the content thereof is not particularly limited, and examples thereof include 0.1 to 10% by weight. From the viewpoint of further improving powder permeability, skin texture, and powder retention, the content of starch acrylate in the external composition of the present invention is preferably 0.1 to 5% by weight, more preferably 0.1 to 5% by weight. Is 0.1 to 3% by weight, particularly preferably 0.1 to 2% by weight, and most preferably 0.1 to 1% by weight.
本発明の外用組成物において、アクリル酸デンプンを含有させる場合、粉体に対するアクリル酸デンプンの比率については、特に制限されないが、例えば、粉体100重量部当たり、アクリル酸デンプンが、1〜200重量部、好ましくは2〜150重量部、更に好ましくは5〜100重量部が挙げられる。 When starch acrylate is contained in the external composition of the present invention, the ratio of starch acrylate to the powder is not particularly limited, but for example, starch acrylate is contained in an amount of 1 to 200 weight per 100 parts by weight of the powder. Parts, preferably 2 to 150 parts by weight, more preferably 5 to 100 parts by weight.
増粘剤
本発明の外用組成物は、適度な粘度を付与して使用感を高めるために、増粘剤が含まれていてもよい。
Thickener The external composition of the present invention may contain a thickener in order to impart an appropriate viscosity and enhance the usability.
増粘剤の種類については、香粧学的に許容されることを限度として特に制限されないが、例えば、カルボキシビニルポリマー、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロースナトリウム、エチルセルロース、メチルセルロース、アルギン酸ナトリウム、キサンタンガム、カラギーナン、ポリビニルピロリドン等が挙げられる。これらの増粘剤の中でも、好ましくはカルボキシビニルポリマーが挙げられる。 The type of thickener is not particularly limited as long as it is cosmetically acceptable, and for example, carboxyvinyl polymer, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, ethylcellulose, methylcellulose, sodium alginate, xanthan gum, carrageenan, etc. Polyvinylpyrrolidone and the like can be mentioned. Among these thickeners, a carboxyvinyl polymer is preferably mentioned.
これらの増粘剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These thickeners may be used alone or in combination of two or more.
本発明の外用組成物に増粘剤を含有させる場合、その含有量については、特に制限されないが、例えば、0.1〜5重量%、好ましくは0.1〜2重量%、更に好ましくは0.1〜1重量%が挙げられる。 When the external composition of the present invention contains a thickener, the content thereof is not particularly limited, but is, for example, 0.1 to 5% by weight, preferably 0.1 to 2% by weight, more preferably 0. .1 to 1% by weight.
水
本発明の外用組成物は、ヘパリン類似物質を溶解させた状態にして、粉体分散安定性を効果的に向上させるために、水が含まれていることが好ましい。本発明の外用組成物において水を含有させる場合、その含有量については、特に制限されないが、例えば30重量%以上、好ましくは30〜95重量%、更に好ましくは40〜95重量%が挙げられる。
Composition for external use of the water present invention, in the state of being dissolved heparinoid, in order to effectively improve the powder dispersion stability, it preferably contains water. When water is contained in the external composition of the present invention, the content thereof is not particularly limited, and examples thereof include 30% by weight or more, preferably 30 to 95% by weight, and more preferably 40 to 95% by weight.
油分
本発明の外用組成物は、皮膚に塗布した際の使用感の向上等のために、油分が含まれていてもよい。
Oil content The external composition of the present invention may contain an oil content in order to improve the usability when applied to the skin.
油分の種類については、香粧学的に許容されることを限度として特に制限されないが、例えば、オリーブ油、サフラワー油、大豆油、つばき油、とうもろこし油、なたね油、ひまわり油、綿実油、落花生油、ラード、スクワラン、魚油等の動植物油;流動パラフィン、パラフィン、ゲル化炭化水素、ワセリン等の鉱物油;ミツロウ、カルナウバロウ、キャンデリラロウ、セレシン、ライスワックス、マイクロクリスタリンワックス等のワックス類・ロウ類;ミリスチン酸イソプロピル、アジピン酸イソプロピル、セバシン酸ジエチル、セバシン酸イソプロピル、パルミチン酸イソプロピル、パルミチン酸セチル、オレイン酸エチル等のエステル油;ステアリン酸、オレイン酸、パルミチン酸、ベヘン酸、リノール酸、ラノリン等の脂肪酸;パルミチン酸セチル、パルミチン酸イソプロピル、リノール酸エチル等の脂肪酸エステル;ステアリルアルコール、セタノール、ベヘニルアルコール、ミリスチルアルコール、オレイルアルコール、ヘキサデシルアルコール、ラノリンアルコール等の高級アルコール;ジメチルポリシロキサン、環状シリコーン等のシリコーンオイル;コレステロール、トリ2−エチルヘキサン酸グリセリル、2−エチルヘキサン酸セチル等が挙げられる。これらの油分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The type of oil is not particularly limited as long as it is cosmetically acceptable, but for example, olive oil, saflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, etc. Animal and vegetable oils such as lard, squalane, fish oil; mineral oils such as liquid paraffin, paraffin, gelled hydrocarbons, and vaseline; waxes and waxes such as beeswax, carnauba wax, candelilla wax, ceresin, rice wax, and microcrystallin wax; Ester oils such as isopropyl myristate, isopropyl adipate, diethyl sebacate, isopropyl sebacate, isopropyl palmitate, cetyl palmitate, ethyl oleate; stearic acid, oleic acid, palmitic acid, bechenic acid, linoleic acid, lanolin, etc. Fatty acids; fatty acid esters such as cetyl palmitate, isopropyl palmitate, ethyl linoleate; higher alcohols such as stearyl alcohol, cetanol, behenyl alcohol, myristyl alcohol, oleyl alcohol, hexadecyl alcohol, lanolin alcohol; dimethylpolysiloxane, cyclic silicone, etc. Silicone oils; examples include cholesterol, glyceryl tri2-ethylhexanoate, cetyl 2-ethylhexanoate and the like. These oils may be used alone or in combination of two or more.
本発明の外用組成物に油分を含有させる場合、その含有量については、製剤形態等に応じて適宜設定すればよいが、例えば、1〜50重量%、好ましくは5〜50重量%が挙げられる。 When the external composition of the present invention contains an oil, the content thereof may be appropriately set according to the formulation form and the like, and examples thereof include 1 to 50% by weight, preferably 5 to 50% by weight. ..
界面活性剤
また、本発明の外用組成物は、必要に応じて、界面活性剤が含まれていてもよい。特に、本発明の外用組成物に油分を配合する場合であれば、油分を可溶化又は乳化させるために界面活性剤が含まれていることが望ましい。
Surfactant Further , the external composition of the present invention may contain a surfactant, if necessary. In particular, when an oil component is added to the external composition of the present invention, it is desirable that a surfactant is contained in order to solubilize or emulsify the oil component.
界面活性剤としては、香粧学的に許容されることを限度として特に制限されず、ノニオン性界面活性剤、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤のいずれを使用してもよいが、好ましくはノニオン性界面活性剤が挙げられる。 The surfactant is not particularly limited as long as it is cosmetically acceptable, and any of nonionic surfactant, anionic surfactant, cationic surfactant, and amphoteric surfactant is used. However, a nonionic surfactant is preferable.
界面活性剤としては、具体的には、POE(10〜50モル)フィトステロールエーテル、POE(10〜50モル)ジヒドロコレステロールエーテル、POE(10〜50モル)2−オクチルドデシルエーテル、POE(10〜50モル)デシルテトラデシルエーテル、POE(10〜50モル)オレイルエーテル、POE(2〜50モル)セチルエーテル、POE(5〜50モル)ベヘニルエーテル、POE(5〜30モル)ポリオキシプロピレン(5〜30モル)2−デシルテトラデシルエーテル、POE(10〜50モル)ポリオキシプロピレン(2〜30モル)セチルエーテル等のポリオキシエチレンアルキルエーテル、これらのリン酸・リン酸塩(POEセチルエーテルリン酸ナトリウムなど)、POE(20〜60モル)ソルビタンモノオレート、POE(10〜60モル)ソルビタンモノイソステアレート、POE(10〜80モル)グリセリルモノイソステアレート、POE(10〜30モル)グリセリルモノステアレート、POE(20〜100モル)・ポリオキシプロピレン変性シリコーン、POE・アルキル変性シリコーン、モノラウリン酸ポリエチレングリコール、モノパルミチン酸ポリエチレングリコール、モノステアリン酸ポリエチレングリコール、ジラウリン酸ポリエチレングリコール、ジパルミチン酸ポリエチレングリコール、ジステアリン酸ポリエチレングリコール、ジオレイン酸ポリエチレングリコール、ジリシノレイン酸ポリエチレングリコール、ポリオキシエチレン硬化ヒマシ油(5〜100)、ポリソルベート(20〜85)、グリセリン脂肪酸エステル(モノステアリン酸グリセリン等)、水素添加大豆リン脂質、水素添加ラノリンアルコール、脂肪酸ポリグリセリル(ステアリン酸ポリグリセリル等)、アミノ酸と脂肪酸のアミド結合物(ステアロイルグルタミン酸ナトリウム等)が挙げられる。これらの界面活性剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Specific examples of the surfactant include POE (10 to 50 mol) phytosterol ether, POE (10 to 50 mol) dihydrocholesterol ether, POE (10 to 50 mol) 2-octyldodecyl ether, and POE (10 to 50 mol). Mol) decyltetradecyl ether, POE (10-50 mol) oleyl ether, POE (2-50 mol) cetyl ether, POE (5-50 mol) behenyl ether, POE (5-30 mol) polyoxypropylene (5-mol) Polyoxyethylene alkyl ethers such as 30 mol) 2-decyltetradecyl ether, POE (10 to 50 mol) polyoxypropylene (2 to 30 mol) cetyl ether, and their phosphates and phosphates (POE cetyl ether phosphoric acid). Sodium, etc.), POE (20-60 mol) sorbitan monoolate, POE (10-60 mol) sorbitan monoisostearate, POE (10-80 mol) glyceryl monoisostearate, POE (10-30 mol) glyceryl mono Steerate, POE (20-100 mol) polyoxypropylene-modified silicone, POE-alkyl-modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate, polyethylene glycol dipalmitate , Polyethylene glycol distearate, Polyethylene glycol dioleate, Polyethylene glycol diricinoleate, Polyoxyethylene hydrogenated castor oil (5-100), Polysorbate (20-85), Glycerin fatty acid ester (Glycerin monostearate, etc.), Hydrogenated soybean Examples thereof include phospholipids, hydrogenated lanolin alcohol, polyglyceryl fatty acid (polyglyceryl stearate, etc.), and amide conjugates of amino acids and fatty acids (sodium stearoyl glutamate, etc.). These surfactants may be used alone or in combination of two or more.
本発明の外用組成物に、界面活性剤を含有させる場合、その含有量については、製剤形態等に応じて適宜設定すればよいが、例えば、0.1〜10重量%、好ましくは0.1〜8重量%、更に好ましくは0.1〜5重量%が挙げられる。 When the external composition of the present invention contains a surfactant, the content thereof may be appropriately set according to the formulation form and the like, and is, for example, 0.1 to 10% by weight, preferably 0.1. -8% by weight, more preferably 0.1 to 5% by weight.
その他の成分
本発明の外用組成物は、前述する成分の他に、必要に応じて、香粧学的又は薬学的な機能性を示す機能性成分が含まれていてもよい。このような機能性成分としては、特に制限されないが、例えば、水溶性のビタミン及びその誘導体、油溶性のビタミン及びその誘導体、グリチルリチン酸及びその誘導体、グリチルレチン酸及びその誘導体、アスタキサンチン、コエンザイムQ10、α−リポ酸、セラミド又はその類似物質、リノール酸、アルブチン、トラネキサム酸、コウジ酸、酵素、ペプチド、ホルモン、各種サイトカイン、ヒアルロン酸等のグリコサミノグリカン類及びその塩類或いはその誘導体、ヒアルロン酸加水分解物、コラーゲン又はその加水分解物、エラスチン又はその加水分解物、糖類等の生理活性物質、各種動植物抽出物、微生物による発酵で得られる物質、ステロイド剤、抗ヒスタミン、局所麻酔剤、抗炎症剤、抗菌剤、抗菌剤、鎮痒剤、皮膚保護剤、血行促進剤、ステロール類等が挙げられる。これらの機能性成分を含有させる場合、その含有量については、使用する機能性成分の種類、期待する効果等に応じて適宜設定すればよい。
Other Ingredients In addition to the above-mentioned ingredients, the external composition of the present invention may contain functional ingredients exhibiting cosmetic or pharmaceutical functionality, if necessary. Such functional components are not particularly limited, but are, for example, water-soluble vitamins and derivatives thereof, oil-soluble vitamins and derivatives thereof, glycyrrhizinic acid and derivatives thereof, glycyrrhetinic acid and derivatives thereof, astaxanthin, coenzyme Q10, α. -Glycosaminoglycans such as lipoic acid, ceramide or similar substances, linoleic acid, arbutin, tranexamic acid, kodiic acid, enzymes, peptides, hormones, various cytokines, hyaluronic acid and salts thereof or derivatives thereof, hyaluronic acid hydrolysis Substances, collagen or its hydrolyzate, elastin or its hydrolyzate, physiologically active substances such as sugars, various animal and plant extracts, substances obtained by fermentation by microorganisms, steroids, antihistamine, local anesthetics, anti-inflammatory agents, Examples thereof include antibacterial agents, antibacterial agents, antipruritic agents, skin protectants, blood circulation promoters, sterols and the like. When these functional components are contained, the content thereof may be appropriately set according to the type of the functional component to be used, the expected effect, and the like.
また、本発明の外用組成物は、所望の製剤形態にするために、必要に応じて、前述する成分以外の添加剤が含まれていてもよい。このような添加剤については、香粧学的に許容されることを限度として特に制限されないが、例えば、多価アルコール(エチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、グリセリン等)、一価の低級アルコール(エタノール、プロパノール、イソプロパノール、ブタノール、イソブタノール等)、清涼化剤(メントール、カンフル、ボルネオール、ハッカ水、ハッカ油等)、防腐剤(メチルパラベン、プロピルパラベン、安息香酸、安息香酸ナトリウム、ソルビン酸等)、着香剤(シトラール、1,8−シオネール、シトロネラール、ファルネソール等)、着色剤(タール色素(褐色201号、青色201号、黄色4号、黄色403号等)、カカオ色素、クロロフィル、酸化アルミニウム等)、pH調整剤(リン酸、塩酸、クエン酸、クエン酸ナトリウム、コハク酸、酒石酸、水酸化ナトリウム、水酸化カリウム、トリエタノールアミン、トリイソプロパノールアミン等)、湿潤剤(dl−ピロリドンカルボン酸ナトリウム液、D−ソルビトール液、マクロゴール等)、安定化剤(ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、エデト酸ナトリウム、メタリン酸ナトリウム、L−アルギニン、L−アスパラギン酸、DL−アラニン、グリシン、エリソルビン酸ナトリウム、没食子酸プロピル、亜硫酸ナトリウム、二酸化硫黄、クロロゲン酸、カテキン、ローズマリー抽出物等)、酸化防止剤、紫外線吸収剤、キレート剤、粘着剤、緩衝剤、溶解補助剤、可溶化剤、保存剤等の添加剤が挙げられる。 In addition, the external composition of the present invention may contain additives other than the above-mentioned components, if necessary, in order to obtain a desired pharmaceutical form. Such additives are not particularly limited as long as they are cosmetically acceptable, but for example, polyhydric alcohols (ethylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polypropylene glycol, glycerin). Etc.), monohydric lower alcohols (ethanol, propanol, isopropanol, butanol, isobutanol, etc.), refreshing agents (menthol, camphor, borneol, peppermint water, peppermint oil, etc.), preservatives (methylparaben, propylparaben, benzoic acid, etc.) , Sodium benzoate, sorbic acid, etc.), flavoring agents (citral, 1,8-cionale, citronellal, farnesol, etc.), colorants (tar pigments (brown 201, blue 201, yellow 4, yellow 403, etc.) ), Cacao pigment, chlorophyll, aluminum oxide, etc.), pH adjuster (phosphoric acid, hydrochloric acid, citric acid, sodium citrate, succinic acid, tartaric acid, sodium hydroxide, potassium hydroxide, triethanolamine, triisopropanolamine, etc.) , Wetting agent (dl-pyrrolidone sodium carboxylate solution, D-sorbitol solution, macrogol, etc.), stabilizer (dibutylhydroxytoluene, butylhydroxyanisole, sodium edetate, sodium metaphosphate, L-arginine, L-aspargonic acid) , DL-alanine, glycine, sodium erythorbate, propyl gallate, sodium sulfite, sulfur dioxide, chlorophosphoric acid, catechin, rosemary extract, etc.), antioxidants, UV absorbers, chelating agents, adhesives, buffers, Additives such as solubilizers, solubilizers and preservatives can be mentioned.
製剤形態・用途
本発明の外用組成物は、経皮適用される製剤(化粧料、外用医薬品(医薬部外品を含む)等)として使用される。
Formulation Form / Use The external composition of the present invention is used as a transdermally applied preparation (cosmetics, external pharmaceuticals (including quasi-drugs), etc.).
本発明の外用組成物の剤型については、特に制限されず、液状(懸濁液、乳化液等)、半固形状(クリーム、軟膏、ジェル等)、又は固形状のいずれであってもよいが、好ましくは液状及び半固形状が挙げられる。 The dosage form of the external composition of the present invention is not particularly limited and may be liquid (suspension, emulsion, etc.), semi-solid (cream, ointment, gel, etc.), or solid. However, liquid and semi-solid forms are preferable.
本発明の外用組成物の製剤形態については、経皮適用可能であることを限度として特に制限されず、例えば、メイクアップ化粧料(ファンデーション、コンシーラー、チーク等)、クリーム、化粧水、美容液、乳液、ジェル、口紅、ファンデーション等の化粧料;液剤(ローション剤、スプレー剤、エアゾール剤、及び乳液剤を含む)、フォーム剤、軟膏剤、クリーム剤、ジェル剤等の外用医薬品が挙げられる。これらの製剤形態の中でも、好ましくは化粧料、更に好ましくは、クリーム、化粧水、美容液、乳液、ジェル等が挙げられる。 The formulation form of the external composition of the present invention is not particularly limited as long as it can be applied transdermally, and for example, make-up cosmetics (foundation, concealer, teak, etc.), creams, lotions, beauty liquids, etc. Cosmetics such as emulsions, gels, lipsticks and foundations; external preparations such as liquids (including lotions, sprays, aerosols and emulsions), foams, ointments, creams and gels. Among these pharmaceutical forms, cosmetics are preferable, and creams, lotions, beauty essences, milky lotions, gels and the like are more preferable.
本発明の外用組成物は、シワ及び/又は毛穴の隠蔽(シワ隠し及び/又は毛穴隠し)用途に使用される。本発明の外用組成物が適用される部位については、特に制限されず、シワが生じている部位、及び/又は毛穴が目立つ部位であればよいが、例えば、顔、首、手、腕、足等が挙げられる。 The external composition of the present invention is used for wrinkle and / or pore concealment (wrinkle concealment and / or pore concealment) application. The site to which the external composition of the present invention is applied is not particularly limited as long as it is a site where wrinkles occur and / or a site where pores are conspicuous. For example, the face, neck, hands, arms, and feet. And so on.
以下に、実施例等を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples and the like, but the present invention is not limited thereto.
なお、以下の実施例、比較例、及び処方例において、アクリル酸デンプン1000は商品名「サンウェットサンウェットIM−1000MPS」(三洋化成工業株式会社製)、アクリル酸デンプン300は商品名「サンウェットIM−300MPS」(三洋化成工業株式会社製)、デンプン・アクリル酸ナトリウムグラフト重合体は商品名「サンフレッシュST−100MC」(三洋化成工業株式会社製)を使用した。 In the following examples, comparative examples, and formulation examples, starch acrylate 1000 has a trade name of "Sunwet Sunwet IM-1000MPS" (manufactured by Sanyo Chemical Industries, Ltd.), and starch acrylate 300 has a trade name of "Sunwet". "IM-300MPS" (manufactured by Sanyo Chemical Industries, Ltd.) and starch-sodium acrylate graft polymer used the trade name "Sunfresh ST-100MC" (manufactured by Sanyo Chemical Industries, Ltd.).
試験例1
1.外用組成物(懸濁液)の調製
表1に示す組成の外用組成物(懸濁液)を調製した。具体的には、先ず、精製水にヘパリン類似物質及びアクリル酸デンプン1000を加えて溶解させた。次いで、表1に示す各粉体を加えて混合することにより、外用組成物(懸濁液)を得た。
Test Example 1
1. 1. Preparation of External Composition (Suspension) An external composition (suspension) having the composition shown in Table 1 was prepared. Specifically, first, a heparinoid and starch acrylate 1000 were added to purified water and dissolved. Then, each powder shown in Table 1 was added and mixed to obtain an external composition (suspension).
2.分散安定性の評価方法
調製後の外用組成物を室温にて5分間静置した後に、外観を観察することにより粉体の分散性安定性の評価を行った。分散安定性は、以下の基準に従って判定した。
2. Evaluation Method of Dispersion Stability After the prepared external composition was allowed to stand at room temperature for 5 minutes, the dispersion stability of the powder was evaluated by observing the appearance. Dispersion stability was determined according to the following criteria.
○:粉体が均一に分散している。
△:粉体が沈降し、液の一部が透明になっている。
×:全ての粉体が底部まで沈降し、粉体が沈降している部分を除く液のほぼ全部が透明になる。
◯: The powder is uniformly dispersed.
Δ: The powder has settled and a part of the liquid has become transparent.
X: All the powder settles to the bottom, and almost all of the liquid except the part where the powder has settled becomes transparent.
3.評価結果
得られた結果を表1に示す。また、実施例7及び比較例5の外用組成物を5分間静置した後の外観を観察した写真を図1に示す。粉体のみを含む場合には、粉体の沈降が認められ、粉体の分散安定性が悪かった(比較例1〜5)。これに対して、粉体及びアクリル酸デンプンと共にヘパリン類似物質を含む場合には、粉体が沈降することなく、粉体の分散安定性が著しく向上していた(実施例1〜7)。
3. 3. Evaluation Results Table 1 shows the results obtained. Further, FIG. 1 shows a photograph of the external compositions of Example 7 and Comparative Example 5 observed after being allowed to stand for 5 minutes. When only the powder was contained, sedimentation of the powder was observed, and the dispersion stability of the powder was poor (Comparative Examples 1 to 5). On the other hand, when the heparin-like substance was contained together with the powder and starch acrylate, the powder did not settle and the dispersion stability of the powder was significantly improved (Examples 1 to 7).
更に、ヘパリン類似物質と共に、粉体として酸化鉄を含む実施例4及び5では、ヘパリン類似物質を含まない比較例3及び4に比べて、色調が明るくなって発色性が向上していた。即ち、本結果から、ヘパリン類似物質及び酸化鉄を含む外用組成物は、シワを目立たなくするのに特に好適であることも確認された。 Further, in Examples 4 and 5 containing iron oxide as a powder together with the heparinoid, the color tone was brighter and the color development was improved as compared with Comparative Examples 3 and 4 not containing the heparinoid. That is, from this result, it was also confirmed that the external composition containing a heparinoid and iron oxide is particularly suitable for making wrinkles inconspicuous.
試験例2
1.外用組成物(乳化組成物)の調製
表2に示す組成の外用組成物(乳化組成物)を調製した。具体的には、カルボキシビニルポリマーを適量の精製水に混合、撹拌し、水相画分1を得た。別途、表2のCの欄に示す成分を80℃で加熱溶解し、油相画分を得た。また、ヘパリン類似物質を適量の精製水に混合、撹拌し、水相画分2を得た。水相画分1に、表2のBの欄に示す粉体と水相画分2を混合した後に、油相画分を加えて、ホモミキサーにより乳化処理を行い、乳化させた。次いで、リン酸を添加することにより、pH5.0の外用組成物(クリーム状の組成物)を得た。
Test Example 2
1. 1. Preparation of External Composition (Emulsified Composition) An external composition (emulsified composition) having the composition shown in Table 2 was prepared. Specifically, the carboxyvinyl polymer was mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 1. Separately, the components shown in column C of Table 2 were heated and dissolved at 80 ° C. to obtain an oil phase fraction. Further, a heparinoid was mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 2. After mixing the powder shown in column B of Table 2 and the aqueous phase fraction 2 with the aqueous phase fraction 1, the oil phase fraction was added, and emulsification treatment was performed with a homomixer to emulsify. Then, by adding phosphoric acid, an external composition (creamy composition) having a pH of 5.0 was obtained.
2.分散安定性の評価方法
調製後の外用組成物の外観を観察することにより粉体の分散性安定性の評価を行った。分散安定性は、以下の基準に従って判定した。
2. Evaluation method of dispersion stability The dispersibility stability of the powder was evaluated by observing the appearance of the external composition after preparation. Dispersion stability was determined according to the following criteria.
○:粉体が均一に分散している。
×:粉体が均一に分散できておらず、ダマが生じている。
◯: The powder is uniformly dispersed.
X: The powder is not uniformly dispersed and lumps are generated.
3.評価結果
得られた結果を表2に示す。粉体と共にヘパリン類似物質を含む場合には、ダマを生じさせることなく、粉体を均一に分散できていた(実施例8〜11)。また、アクリル酸デンプン及びヘパリン類似物質と共に、粉体として酸化鉄を含む実施例11では、色調が明るくなって発色性が向上しており、シワを目立たなくするのに特に好適であることも確認された。
3. 3. Evaluation Results Table 2 shows the results obtained. When heparinoids were contained together with the powder, the powder could be uniformly dispersed without causing lumps (Examples 8 to 11). It was also confirmed that in Example 11 containing iron oxide as a powder together with starch acrylate and a heparinoid, the color tone was brightened and the color development was improved, which was particularly suitable for making wrinkles inconspicuous. Was done.
試験例3
1.外用組成物(乳化組成物)の調製
表3に示す組成の外用組成物(乳化組成物)を調製した。具体的には、カルボキシビニルポリマーを適量の精製水に混合、撹拌し、水相画分1を得た。また、表1のDの欄に示す成分を80℃で加熱溶解し、油相画分を得た。更に、アクリル酸デンプン1000を適量の精製水に混合、撹拌し、水相画分2を得た。水相画分1に、表1のCの欄に示す粉体と水相画分2を混合した後に、油相画分を加えて、ホモミキサーにより乳化処理を行い、乳化させた。次いで、リン酸を添加することにより、pH5.0の外用組成物(クリーム状の乳化組成物)を得た。
Test Example 3
1. 1. Preparation of External Composition (Emulsified Composition) An external composition (emulsified composition) having the composition shown in Table 3 was prepared. Specifically, the carboxyvinyl polymer was mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 1. Further, the components shown in column D of Table 1 were heated and dissolved at 80 ° C. to obtain an oil phase fraction. Further, starch 1000 acrylate was mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 2. After mixing the powder shown in column C of Table 1 and the aqueous phase fraction 2 with the aqueous phase fraction 1, the oil phase fraction was added, and emulsification treatment was performed with a homomixer to emulsify. Then, by adding phosphoric acid, an external composition (creamy emulsified composition) having a pH of 5.0 was obtained.
2.分散安定性の評価方法
前記試験例2と同様の方法で、粉体の分散安定性について評価した。
2. Evaluation Method of Dispersion Stability The dispersion stability of the powder was evaluated by the same method as in Test Example 2 above.
3.シワの隠蔽効果の評価方法
得られた各外用組成物を用いて、シワの隠蔽効果を確認するために、粉体侵入性、肌質感、及び粉体保持性の評価を行った。具体的な評価方法は、以下に示す通りである。
3. 3. Evaluation Method of Wrinkle Concealing Effect Using each of the obtained external compositions, powder permeability, skin texture, and powder retention were evaluated in order to confirm the wrinkle concealing effect. The specific evaluation method is as shown below.
[粉体侵入性]
手の甲のシワが気になるモニター10名に対して、外用組成物の塗布により、塗布部のシワを埋めることができるか否か評価した。具体的には、外用組成物0.3gを手の甲に塗布し、1分間馴染ませた後に、目視にて観察し、粉体によってシワを埋めることができたかを評価した。シワがきれいに埋まったと感じた人の人数をカウントし、以下の基準により粉体侵入性を判定した。
◎:8〜10人
○:5〜7人
△:2〜4人
×:0〜1人
[Powder permeability]
For 10 monitors who were worried about wrinkles on the back of their hands, it was evaluated whether or not the wrinkles on the coated portion could be filled by applying the external composition. Specifically, 0.3 g of the external composition was applied to the back of the hand, allowed to acclimatize for 1 minute, and then visually observed to evaluate whether the wrinkles could be filled with the powder. The number of people who felt that the wrinkles were completely filled was counted, and the powder permeability was judged according to the following criteria.
◎: 8 to 10 people ○: 5 to 7 people △: 2 to 4 people ×: 0 to 1 people
[肌質感]
手の甲のシワが気になるモニター10名に対して、外用組成物の塗布により、塗布部のシワが、本来の肌部分と違和感なく視覚的に似た肌質になっているか否か評価した。具体的には、外用組成物0.3gを手の甲に塗布し、1分間馴染ませた後に、目視にて観察し、塗布部のシワが、本来の肌部分と違和感なく視覚的同じ肌質になってシワが目立ちにくくなったか評価した。シワが、本来の肌部分と違和感なく視覚的に似た肌質になってシワが目立ちにくくなったと感じた人の人数をカウントし、以下の基準により肌質感を判定した。
◎:8〜10人
○:5〜7人
△:2〜4人
×:0〜1人
[Skin texture]
For 10 monitors who were worried about wrinkles on the back of their hands, it was evaluated whether or not the wrinkles on the applied portion were visually similar to the original skin part by applying the external composition. Specifically, 0.3 g of the external composition is applied to the back of the hand, allowed to acclimatize for 1 minute, and then visually observed. It was evaluated whether the wrinkles became less noticeable. The number of people who felt that the wrinkles became visually similar to the original skin part and the wrinkles became less noticeable was counted, and the skin texture was judged according to the following criteria.
◎: 8 to 10 people ○: 5 to 7 people △: 2 to 4 people ×: 0 to 1 people
[粉体保持性]
手の甲にシワが気になるモニター10名に対して、塗布した外用組成物が取れにくいか否か評価した。具体的には、外用組成物0.3gを手の甲に塗布し、1分間馴染ませた後に、3回素手で撫でながら流水で洗い、外用組成物が手のシワ部分から除去され難いかを評価した。外用組成物が手のシワ部分から除去され難いと感じた人の人数をカウントし、以下の基準により粉体保持性を判定した。
○:7〜10人
△:3〜6人
×:0〜2人
[Powder retention]
Ten monitors who were worried about wrinkles on the back of their hands were evaluated to see if the applied external composition was difficult to remove. Specifically, 0.3 g of the external composition was applied to the back of the hand, allowed to acclimatize for 1 minute, and then washed with running water while stroking with bare hands three times to evaluate whether the external composition was difficult to remove from the wrinkled part of the hand. .. The number of people who felt that the external composition was difficult to remove from the wrinkled part of the hand was counted, and the powder retention was judged according to the following criteria.
○: 7 to 10 people △: 3 to 6 people ×: 0 to 2 people
4.評価結果
得られた結果を表3に示す。前記試験例2の結果と同様に、粉体とヘパリン類似物質を含む場合には、ダマを生じさせることなく、粉体を均一に分散できていた(実施例12〜24)。
4. Evaluation Results Table 3 shows the results obtained. Similar to the result of Test Example 2, when the powder and the heparinoid were contained, the powder could be uniformly dispersed without causing lumps (Examples 12 to 24).
また、粉体単独の場合には、粉体侵入性は良好であったものの、肌質感及び粉体保持性の点で不十分であった(比較例7)。これに対して、粉体とアクリル酸デンプンを併用した場合には、粉体侵入性、肌質感、及び粉体保持性が良好であり、優れたシワ隠蔽効果を有していた(実施例12〜24)。また、平均粒子径0.6〜16μmのいずれの粉体でも、アクリル酸デンプンとの併用によって、粉体侵入性、肌質感、及び粉体保持性が良好になることも確認された。また、実施例15と実施例24との対比から明らかなように、アクリル酸デンプンは、肌質感、及び粉体保持性の向上に寄与するだけでなく、粉体侵入性を向上させる作用を有していることも確認された。 Further, in the case of powder alone, although the powder permeability was good, it was insufficient in terms of skin texture and powder retention (Comparative Example 7). On the other hand, when the powder and starch acrylate were used in combination, the powder permeability, the texture of the skin, and the powder retention were good, and the wrinkle concealing effect was excellent (Example 12). ~ 24). It was also confirmed that any powder having an average particle size of 0.6 to 16 μm has good powder permeability, skin texture, and powder retention when used in combination with starch acrylate. Further, as is clear from the comparison between Examples 15 and 24, starch acrylate not only contributes to the improvement of skin texture and powder retention, but also has the effect of improving powder permeability. It was also confirmed that it was done.
実施例13と14を対比すると、実施例14の方が肌質感がよいと感じた人が多く、また、肌質感の評価結果が○になった実施例の中では、実施例22及び23が、シワが目立ちにくくなったと感じた人の人数が最多の7人であった。この結果から、粉体として、屈折率が2.2〜2.8程度の粉体(酸化チタン)と屈折率が1.3〜2.0程度の粉体(二酸化ケイ素)を併用することにより、より一層優れた肌質感を表出できることが明らかとなった。
Comparing Examples 13 and 14, many people felt that Example 14 had a better skin texture, and among the Examples in which the evaluation result of the skin texture was ○, Examples 22 and 23 were shown. , The number of people who felt that wrinkles became less noticeable was 7, which was the largest number. From this result, as a powder, a powder having a refractive index of about 2.2 to 2.8 (titanium oxide) and a powder having a refractive index of about 1.3 to 2.0 (silicon dioxide) are used in combination. , It became clear that even more excellent skin texture can be expressed.
処方例
表4〜6に示す組成の外用組成物(乳化組成物)を調製した。具体的には、カルボキシビニルポリマーを適量の精製水に混合、撹拌し、水相画分1を得た。別途、表4〜6のCの欄に示す成分を80℃で加熱溶解し、油相画分を得た。更に、表4〜6のAの欄に示す成分を適量の精製水に混合、撹拌し、水相画分2を得た。水相画分1に、表4〜6のBの欄に示す粉体と水相画分2を混合した後に、油相画分を加えて、ホモミキサーにより乳化処理を行い、乳化させた。次いで、リン酸を添加することにより、pH5.0の外用組成物(クリーム状の乳化組成物)を得た。得られた外用組成物について、前記試験例2と同様の方法で粉体の分散安定性の評価を行ったところ、いずれも、粉体の均一な分散が確認された。また、前記試験例3と同様の方法でシワ隠蔽効果の評価を行ったところ、いずれの外用組成物でも、粉体侵入性、肌質感、及び粉体保持性が良好であり、優れたシワ隠蔽効果を有していた。
Formulation Examples External compositions (emulsified compositions) having the compositions shown in Tables 4 to 6 were prepared. Specifically, the carboxyvinyl polymer was mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 1. Separately, the components shown in columns C of Tables 4 to 6 were heated and dissolved at 80 ° C. to obtain an oil phase fraction. Further, the components shown in columns A of Tables 4 to 6 were mixed with an appropriate amount of purified water and stirred to obtain an aqueous phase fraction 2. After mixing the powders shown in columns B of Tables 4 to 6 and the aqueous phase fraction 2 into the aqueous phase fraction 1, the oil phase fraction was added and emulsified by a homomixer to emulsify. Then, by adding phosphoric acid, an external composition (creamy emulsified composition) having a pH of 5.0 was obtained. When the dispersion stability of the powder was evaluated for the obtained external composition by the same method as in Test Example 2, uniform dispersion of the powder was confirmed in each case. Further, when the wrinkle concealing effect was evaluated by the same method as in Test Example 3, all the external compositions had good powder penetration, skin texture, and powder retention, and were excellent in wrinkle concealment. It had an effect.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016069071A JP6879670B2 (en) | 2016-03-30 | 2016-03-30 | Topical composition for concealing wrinkles and / or pores |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016069071A JP6879670B2 (en) | 2016-03-30 | 2016-03-30 | Topical composition for concealing wrinkles and / or pores |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017178855A JP2017178855A (en) | 2017-10-05 |
JP6879670B2 true JP6879670B2 (en) | 2021-06-02 |
Family
ID=60003645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016069071A Active JP6879670B2 (en) | 2016-03-30 | 2016-03-30 | Topical composition for concealing wrinkles and / or pores |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6879670B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7063616B2 (en) * | 2017-12-28 | 2022-05-09 | 花王株式会社 | Oil-in-water emulsification composition |
JP7288535B2 (en) * | 2017-12-28 | 2023-06-07 | 花王株式会社 | Oil-in-water emulsion composition |
JP7157554B2 (en) * | 2018-05-24 | 2022-10-20 | ポーラ化成工業株式会社 | External composition containing polymer and metal oxide powder |
JP7044284B1 (en) * | 2021-01-29 | 2022-03-30 | 株式会社東洋新薬 | External skin preparation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009840A1 (en) * | 1994-09-27 | 1996-04-04 | Nycomed Imaging A/S | Contrast agent |
JP2000204014A (en) * | 1999-01-11 | 2000-07-25 | Pola Chem Ind Inc | Cosmetic for sensitive skin |
JP2000204020A (en) * | 1999-01-13 | 2000-07-25 | Pola Chem Ind Inc | Cosmetic for lip |
JP4171151B2 (en) * | 2000-01-18 | 2008-10-22 | ポーラ化成工業株式会社 | Cosmetic powder, cosmetic and method for producing cosmetic powder |
JP2002020294A (en) * | 2000-06-30 | 2002-01-23 | Lion Corp | Skin care preparation |
JP3747369B2 (en) * | 2002-03-25 | 2006-02-22 | 株式会社コーセー | Cosmetics for correcting skin irregularities |
JP2006273806A (en) * | 2005-03-30 | 2006-10-12 | Kose Corp | Cosmetic for eyelash |
JP2009173573A (en) * | 2008-01-24 | 2009-08-06 | Shiseido Co Ltd | Cosmetic |
JP5893896B2 (en) * | 2011-11-10 | 2016-03-23 | 株式会社コーセー | Unevenness correction cosmetic |
JP2014101344A (en) * | 2012-11-16 | 2014-06-05 | Daito Kasei Kogyo Kk | Cosmetic |
-
2016
- 2016-03-30 JP JP2016069071A patent/JP6879670B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017178855A (en) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001002523A (en) | Composition of oil-in-water type emulsion form containing cellulose raw fiber and its use in cosmetic use | |
JP6879670B2 (en) | Topical composition for concealing wrinkles and / or pores | |
TWI530298B (en) | Liquid cosmetic | |
JP4160264B2 (en) | Translucent or transparent cosmetics | |
KR20190036341A (en) | Cosmetic Composition for Reducing Stickiness and Improving Transparency of Emulsion Formulation | |
JP2006137684A (en) | Method for preparing liposome precursor | |
JP6704676B2 (en) | External composition | |
JP2003300856A (en) | Cosmetic composition | |
JP6263346B2 (en) | Skin preparations and cosmetics | |
JP2017048158A (en) | Makeup cosmetic | |
JP2009096769A (en) | Fermented-cellulose-containing cosmetic | |
JP5863225B2 (en) | Skin care composition | |
JP2017178854A (en) | External composition | |
JP4828077B2 (en) | Topical skin preparation | |
JP2021098655A (en) | Skin external composition | |
JP2006306793A (en) | Emulsion type cosmetic | |
JP4594661B2 (en) | Emulsified composition containing oil-soluble ascorbic acid derivative | |
WO2019027006A1 (en) | Cosmetic | |
TW200916118A (en) | External preparation for skin | |
JP2003306410A (en) | Powder-containing water in oil type emulsion cosmetic | |
RU2383328C2 (en) | Transdermal gel for area around eyes "silky touch" | |
JP2005132828A (en) | Composition for external application | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JP2006151818A (en) | Skin cosmetic | |
JP2003238381A (en) | Cosmetic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190218 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201030 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6879670 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |